RPG Life Sciences to Acquire Raghava Life Sciences' API Business for ₹135 Crore
Quick Brief
RPG Life Sciences is moving to expand its operations by acquiring the active pharmaceutical ingredient (API) and intermediates business of Raghava Life Sciences. The transaction is valued at ₹135 crore. The purchase strengthens RPG Life Sciences' portfolio in the pharmaceutical sector.
What Happened?
RPG Life Sciences has agreed to acquire the API and intermediates business of Raghava Life Sciences for a total consideration of ₹135 crore.
Why It Matters
The acquisition allows RPG Life Sciences to expand its footprint and capabilities within the pharmaceutical API and intermediates market segment.
Key Facts
- RPG Life Sciences is the acquiring entity.
- Raghava Life Sciences is the target of the acquisition.
- The transaction involves the API and intermediates business.
- The deal is valued at ₹135 crore.
Compiled from 1 outlet
Related Stories
Malabar Milma Approves ₹1.72 Crore Subsidy for Cattle Feed in Keralam
Malabar Milma has sanctioned a ₹1.72 crore subsidy aimed at supporting dairy farmers in Keralam. Through this financial backing, cattle feed will be accessible at reduced prices during September 2026. The initiative is being implemented across all primary dairy cooperative societies within the Malabar region.
Kinder Morgan Files Regulation FD Disclosure with SEC
Kinder Morgan, Inc. has submitted a Form 8-K filing to the U.S. Securities and Exchange Commission. The regulatory filing specifically addresses Item 7.01 concerning Regulation FD Disclosures. The document totals 228 kilobytes in size.
NHAI Terminates Arakkonam-Kancheepuram Builder Contract for Bengaluru-Chennai Expressway
The National Highways Authority of India (NHAI) has officially canceled the construction contract for the Arakkonam-Kancheepuram section of the Bengaluru-Chennai Expressway. To finish the remaining construction, new tenders have been issued under the engineering, procurement, and construction (EPC) mode.
FDA Revokes Drug Sale Licences for Cipla's Pune Facility Over Storage Violations
The food and drug administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences' carry and forwarding unit in Pune. Regulators discovered that pharmaceutical products were being kept directly on the floor. Additionally, authorities identified significant deficiencies in the protocols used for managing expired medicines.